A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma
This is a Phase III, multicentre, open-label, three-arm, randomized study in participants
with unresectable locally advanced or metastatic colorectal cancer (CRC) who have received
at least two prior regimens of cytotoxic chemotherapy for metastatic disease. The study
compares regorafenib, a standard of care therapy in this setting, to cobimetinib plus
atezolizumab and atezolizumab monotherapy.
View this trial on ClinicalTrials.gov
Print this page and take it to your doctor to discuss your eligibilty and treatment options. Only your doctor can refer you to a clinical trial.
These resources are provided in partnership with the
Canadian Cancer Society